This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Herr, H. W. Articles by Whitmore, W. F. Search for Related Content PubMed PubMed Citation Articles by Herr, H. W. Articles by Whitmore, W. F., Jr

Decreased Ability of Blood Leukocytes from Patients with Tumors of the Urinary Bladder to Act as Stimulator Cells in Mixed Leukocyte Culture¹

Laboratory of Tumor-Host Immunology and the Urology Service, Memorial Sloan-Kettering Cancer Center, New York, New York 10021

Blood leukocytes from patients with active neoplasms of the urinary bladder were found to have a decreased ability to stimulate in one-way mixed leukocyte culture (MLC). The ability of the patients' leukocytes to act as stimulator cells in one-way MLC was assessed by simultaneous comparison to the ability of leukocytes from normal individuals to stimulate. In addition, the ability of the patients' leukocytes to act as responder cells in the one-way MLC was evaluated. Cells from 31 (56%) of 55 patients with active disease exhibited subnormal stimulatory activity in the MLC while 26 of these 31 patients (84%) had normal responsiveness. Cells from 9 of the 55 failed to respond normally. Poor stimulation occurred with both early and advanced disease, and the stimulatory activity increased after tumor removal in 12 of 15 patients who had previously shown subnormal stimulation. Six patients without active disease at the time of testing, in addition to the 55, exhibited normal levels of stimulation and responsiveness. This defective stimulatory activity is suggestive of an acquired, disease-related phenomenon and is not necessarily associated with decreased blood leukocyte responsiveness.

¹ Supported in part by NIH Grants CA-08748, CA-17404, and CA-16945 from the National Bladder Cancer Task Force.

² Clinical Fellow, American Cancer Society.

³ Present address: Virginia Mason Research Center, 1000 Seneca St., Seattle, Wash. 98101.

Received 10/31/75. Accepted 4/15/76.

This article has been cited by other articles:

				S. A. Boorjian, Y. Sheinin, P. L. Crispen, S. A. Farmer, C. M. Lohse, S. M. Kuntz, B. C. Leibovich, E. D. Kwon, and I. Frank T-Cell Coregulatory Molecule Expression in Urothelial Cell Carcinoma: Clinicopathologic Correlations and Association with Survival Clin. Cancer Res., August 1, 2008; 14(15): 4800 - 4808. [Abstract] [Full Text] [PDF]